

Beverly A Teicher

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7916199/publications.pdf>

Version: 2024-02-01

53
papers

6,813
citations

126858

33
h-index

168321

53
g-index

57
all docs

57
docs citations

57
times ranked

11713
citing authors

#	ARTICLE	IF	CITATIONS
1	CXCL12 (SDF-1)/CXCR4 Pathway in Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 2927-2931.	3.2	1,159
2	Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 433-443.	1.9	627
3	Hypoxia and drug resistance. <i>Cancer and Metastasis Reviews</i> , 1994, 13, 139-168.	2.7	493
4	Antibody-drug conjugates for cancer therapy. <i>Lancet Oncology</i> , The, 2016, 17, e254-e262.	5.1	439
5	Tumor Evasion of the Immune System by Converting CD4+CD25 ^{hi} T Cells into CD4+CD25 ^{lo} T Regulatory Cells: Role of Tumor-Derived TGF- β 2. <i>Journal of Immunology</i> , 2007, 178, 2883-2892.	0.4	411
6	Antibody Conjugate Therapeutics: Challenges and Potential. <i>Clinical Cancer Research</i> , 2011, 17, 6389-6397.	3.2	365
7	Comprehensive characterization of the Published Kinase Inhibitor Set. <i>Nature Biotechnology</i> , 2016, 34, 95-103.	9.4	289
8	PARP Inhibitor Activity Correlates with <i>SLFN11</i> Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 523-535.	3.2	252
9	Potential of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. <i>International Journal of Cancer</i> , 1994, 57, 920-925.	2.3	220
10	Combination of Antiangiogenic Therapy With Other Anticancer Therapies: Results, Challenges, and Open Questions. <i>Journal of Clinical Oncology</i> , 2005, 23, 1295-1311.	0.8	196
11	Malignant cells, directors of the malignant process: role of transforming growth factor-beta. <i>Cancer and Metastasis Reviews</i> , 2001, 20, 133-143.	2.7	159
12	Proteasome inhibitors. <i>Biochemical Pharmacology</i> , 2015, 96, 1-9.	2.0	144
13	Transforming Growth Factor- β 2 and the Immune Response to Malignant Disease. <i>Clinical Cancer Research</i> , 2007, 13, 6247-6251.	3.2	141
14	Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw122.	3.0	129
15	Toward a Drug Development Path That Targets Metastatic Progression in Osteosarcoma. <i>Clinical Cancer Research</i> , 2014, 20, 4200-4209.	3.2	127
16	Targeting Cancer Metabolism. <i>Clinical Cancer Research</i> , 2012, 18, 5537-5545.	3.2	125
17	Antitransforming growth factor- β 2 antibody 1D11 ameliorates normal tissue damage caused by high-dose radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 876-881.	0.4	120
18	Perspectives from man's best friend: National Academy of Medicine's Workshop on Comparative Oncology. <i>Science Translational Medicine</i> , 2016, 8, 324ps5.	5.8	108

#	ARTICLE	IF	CITATIONS
19	Pericytes and Endothelial Precursor Cells: Cellular Interactions and Contributions to Malignancy. <i>Cancer Research</i> , 2005, 65, 9741-9750.	0.4	95
20	Newer Cytotoxic Agents: Attacking Cancer Broadly. <i>Clinical Cancer Research</i> , 2008, 14, 1610-1617.	3.2	93
21	Endosialin Protein Expression and Therapeutic Target Potential in Human Solid Tumors: Sarcoma versus Carcinoma. <i>Clinical Cancer Research</i> , 2008, 14, 7223-7236.	3.2	90
22	SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic Signatures. <i>Cell Reports</i> , 2020, 33, 108296.	2.9	86
23	Targets in small cell lung cancer. <i>Biochemical Pharmacology</i> , 2014, 87, 211-219.	2.0	61
24	TGF- β 2 in cancer and as a therapeutic target. <i>Biochemical Pharmacology</i> , 2006, 72, 523-529.	2.0	60
25	An in vitro tumor model: analysis of angiogenic factor expression after chemotherapy. <i>Cancer Research</i> , 2002, 62, 5597-602.	0.4	58
26	Searching for molecular targets in sarcoma. <i>Biochemical Pharmacology</i> , 2012, 84, 1-10.	2.0	56
27	Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA Expression. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2452-2462.	1.9	56
28	TGF β 2-Directed Therapeutics: 2020. , 2021, 217, 107666.		52
29	Dynamics of tumor oxygenation, CD31 staining and transforming growth factor- β 2 levels after treatment with radiation or cyclophosphamide in the rat 13762 mammary carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 1997, 37, 1115-1123.	0.4	50
30	3D Models of the NCI60 Cell Lines for Screening Oncology Compounds. <i>SLAS Discovery</i> , 2017, 22, 473-483.	1.4	48
31	The Promise of Antibody-Drug Conjugates. <i>New England Journal of Medicine</i> , 2012, 367, 1847-1848.	13.9	45
32	Reversal of in vivo drug resistance by the transforming growth factor- β 2 inhibitor decorin. <i>International Journal of Cancer</i> , 1997, 71, 49-58.	2.3	44
33	CD248: A therapeutic target in cancer and fibrotic diseases. <i>Oncotarget</i> , 2019, 10, 993-1009.	0.8	44
34	Bromodomain and hedgehog pathway targets in small cell lung cancer. <i>Cancer Letters</i> , 2016, 371, 225-239.	3.2	41
35	Epigenome-wide DNA methylation analysis of small cell lung cancer cell lines suggests potential chemotherapy targets. <i>Clinical Epigenetics</i> , 2020, 12, 93.	1.8	38
36	Anti-Endosialin Antibody-Drug Conjugate: Potential in Sarcoma and Other Malignancies. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2081-2089.	1.9	31

#	ARTICLE	IF	CITATIONS
37	Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 439-449.	1.1	27
38	Characteristics of human Ewing/PNET sarcoma models. <i>Annals of Saudi Medicine</i> , 2011, 31, 174-182.	0.5	26
39	Immuno-transcriptomic profiling of extracranial pediatric solid malignancies. <i>Cell Reports</i> , 2021, 37, 110047.	2.9	26
40	Are neuroendocrine negative small cell lung cancer and large cell neuroendocrine carcinoma with WT RB1 two faces of the same entity?. <i>Lung Cancer Management</i> , 2019, 8, LMT13.	1.5	25
41	<i>CCR</i> 20th Anniversary Commentary: In the Beginning, There Was PS-341. <i>Clinical Cancer Research</i> , 2015, 21, 939-941.	3.2	23
42	Antibody drug conjugates. <i>Current Opinion in Oncology</i> , 2014, 26, 476-483.	1.1	16
43	Association of expression of epigenetic molecular factors with DNA methylation and sensitivity to chemotherapeutic agents in cancer cell lines. <i>Clinical Epigenetics</i> , 2021, 13, 49.	1.8	14
44	Human tumor xenografts and mouse models of human tumors: re-discovering the models. <i>Expert Opinion on Drug Discovery</i> , 2009, 4, 1295-1305.	2.5	13
45	What Can We Learn about Antibody-Drug Conjugates from the T-DM1 Experience?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e117-e125.	1.8	13
46	Small cell lung carcinoma cell line screen of etoposide/carboplatin plus a third agent. <i>Cancer Medicine</i> , 2017, 6, 1952-1964.	1.3	13
47	Exposure time versus cytotoxicity for anticancer agents. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 359-371.	1.1	13
48	Treatment of Transforming Growth Factor-Beta-Insensitive Mouse Renca Tumor by Transforming Growth Factor-Beta Elimination. <i>Urology</i> , 2008, 72, 225-229.	0.5	9
49	Perspective: Opportunities in recalcitrant, rare and neglected tumors. <i>Oncology Reports</i> , 2013, 30, 1030-1034.	1.2	9
50	SMAC Mimetic/IAP Inhibitor Birinapant Enhances Radiosensitivity of Glioblastoma Multiforme. <i>Radiation Research</i> , 2021, 195, 549-560.	0.7	4
51	Format (2D vs 3D) and media effect target expression and response of patient-derived and standard NSCLC lines to EGFR inhibitors. <i>Cancer Treatment and Research Communications</i> , 2021, 29, 100463.	0.7	2
52	Antibody Drug and Radionuclide Conjugates for GI Cancers. , 2017, , 79-99.		1
53	Tumor Heterogeneity Research and Innovation in Biologically Based Radiation Therapy From the National Cancer Institute Radiation Research Program Portfolio. <i>Journal of Clinical Oncology</i> , 2022, 40, 1861-1869.	0.8	1